Preconception testing

PANDA Infertility can reveal predispositions for the 5 most common rare diseases: cystic fibrosis, spinal muscular atrophy, deafness, fragile X syndrome and phenylketonuria.

Yes and no. It is, of course, possible to hope for luck and try to conceive spontaneously, but then it is necessary to investigate the disease prenatally – i.e. during pregnancy.

In this case, however, it is necessary to take account of the possible artificial termination of the pregnancy due to a genetic defect or the birth of a disabled child. This risk is high.

In addition, certain conditions significantly reduce the likelihood of natural conception or considerably raise the risk of spontaneous miscarriage. This is why, here at Repromeda, we recommend that couples facing such conditions undergo IVF with PGT-M.

If the examination reveals a predisposition for one of the diseases on both sides and there is a risk of it occurring in the child, you can rely on the help of artificial insemination using preimplantation genetic testing (PGT-M) of embryos. Only an embryo that does not contain the mutated gene is transferred into the uterus.

The tests reveal possible genetic predispositions to hereditary diseases, congenital tendencies to miscarry, and allow us to predict embryo development. If you have a history of repeated miscarriages and doctors are unable to find out the exact reason, you can get not only an answer but also a solution to your situation.

The results of the genetic test provide unique information about the causes of infertility in the man or woman, the degree of response of a woman’s ovaries to hormonal stimulation or the risks associated with the administration of hormone replacement therapy after embryo implantation. This makes it possible to tailor treatment even more closely to patients.

PANDA Carrier can do everything that PANDA Infertility can, but detects an additional 106 of the most common monogenic recessive diseases.

In addition to cystic fibrosis, spinal muscular atrophy, fragile X syndrome, deafness and phenylketonuria, it also focuses on visual and hearing impairment and musculoskeletal and skin diseases.

With PANDA Carrier testing, you can make the risk of having a genetically affected child 10-20 times lower.

Yes and no. It is, of course, possible to hope for luck and try to conceive spontaneously, but then it is necessary to investigate the disease prenatally – i.e. during pregnancy.

In this case, however, it is necessary to take account of the possible artificial termination of the pregnancy due to a genetic defect or the birth of a disabled child. This risk is high. In addition, certain conditions significantly reduce the likelihood of natural conception or considerably raise the risk of spontaneous miscarriage. This is why, here at Repromeda, we recommend that couples facing such conditions undergo IVF with PGT-M.

In addition, certain conditions significantly reduce the likelihood of natural conception or considerably raise the risk of spontaneous miscarriage. This is why, here at Repromeda, we recommend that couples facing such conditions undergo IVF with PGT-M.

If the examination reveals that both partners are carriers for a certain disease and there is a risk of it occurring in their offspring, you can rely on the assistance of artificial fertilization using preimplantation genetic testing (PGT-M) of embryos. Thus, only an embryo that does not contain the mutated gene will be transferred to the uterus.

The tests uncover potential genetic predispositions to hereditary diseases, congenital tendencies to miscarriage, and allow for the prediction of embryo development. If you have experienced recurrent miscarriages and doctors have not been able to determine the exact cause, with us you can obtain not only an answer but also a solution to your situation.

The results of the genetic test provide unique information about the causes of infertility in men or women, about the degree of a woman’s ovarian response to hormonal stimulation, or about the risks associated with administering hormone replacement therapy after embryo transfer. This enables even more personalized treatment for patients.